The fluoroquinolones as antibacterial compounds; an overview on biological and chemical activities aspects.

[1]  J. Heidelbaugh,et al.  The perils of prescribing fluoroquinolones. , 2013, The Journal of family practice.

[2]  V. Andriole.  The Future of the Quinolones , 2012, Drugs.

[3]  K. Soni.  Fluoroquinolones: Chemistry & Action – A Review , 2012, Indo Global Journal of Pharmaceutical Sciences.

[4]  F. Mégraud,et al.  Metalloantibiotics: Synthesis, characterization and antimicrobial evaluation of bismuth-fluoroquinolone complexes against Helicobacter pylori , 2009, Acta pharmaceutica.

[5]  N. Wu,et al.  The synthesis and biological evaluation of a novel series of C7 non-basic substituted fluoroquinolones as antibacterial agents. , 2009, Bioorganic & medicinal chemistry letters.

[6]  G. Koren,et al.  The safety of quinolones--a meta-analysis of pregnancy outcomes. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[7]  A. Roy,et al.  STUDIES ON SYNTHESIS AND BIOLOGICAL EVALUATION OF SOME SUBSTITUTED FLUOROQUINOLONES , 2009 .

[8]  P. Tulkens,et al.  Terms and Conditions for Use of Pdf , 2022 .

[9]  A. Mehlhorn,et al.  Infectious Diseases: Safety Concerns with Fluoroquinolones , 2007, The Annals of pharmacotherapy.

[10]  P. Iannini.  The safety profile of moxifloxacin and other fluoroquinolones in special patient populations , 2007, Current medical research and opinion.

[11]  R. Rodloff.  Activities of Quinolones Against Obligately Anaerobic Bacteria , 2007 .

[12]  A. Robicsek,et al.  The worldwide emergence of plasmid-mediated quinolone resistance. , 2006, The Lancet. Infectious diseases.

[13]  A. Gadad,et al.  Synthesis, antibacterial and antitubercular activities of some 7-[4-(5-amino-[1,3,4]thiadiazole-2-sulfonyl)-piperazin-1-yl] fluoroquinolonic derivatives. , 2006, European journal of medicinal chemistry.

[14]  M. Faramarzi,et al.  Synthesis and antibacterial activity of new fluoroquinolones containing a substituted N-(phenethyl)piperazine moiety. , 2006, Bioorganic & medicinal chemistry letters.

[15]  E. Leibovitz.  The use of fluoroquinolones in children , 2006, Current opinion in pediatrics.

[16]  D. Ivanov,et al.  [Ciprofloxacin and antibacterial therapy of respiratory tract infections]. , 2006, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].

[17]  R. Owens,et al.  Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  V. Andriole.  The quinolones: past, present, and future. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  J. Cui,et al.  Syntheses of quinolone hydrochloride enantiomers from synthons (R)- and (S)-2-methylpiperazine. , 2005, Bioorganic & medicinal chemistry.

[20]  A. Bircher,et al.  Hypersensitivity reactions to fluoroquinolones , 2005, Current allergy and asthma reports.

[21]  D. Paterson.  "Collateral damage" from cephalosporin or quinolone antibiotic therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  F. Martinez.  Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  G. Eliopoulos.  Quinolone resistance mechanisms in pneumococci. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  C. D. Rothermel.  Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes? , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  D. Low.  Quinolone resistance among pneumococci: therapeutic and diagnostic implications. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  A. Cloeckaert,et al.  Role of TolC and parC mutation in high-level fluoroquinolone resistance in Salmonella enterica serotype Typhimurium DT204. , 2004, The Journal of antimicrobial chemotherapy.

[27]  R. Moellering.  The continuing challenge of lower respiratory tract infections. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  R. Ilavarasan,et al.  Synthesis of 6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid derivatives as potential antimicrobial agents. , 2003, European journal of medicinal chemistry.

[29]  A. MacGowan,et al.  Development of the quinolones. , 2003, The Journal of antimicrobial chemotherapy.

[30]  P. Tulkens,et al.  Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. , 2003, The Journal of antimicrobial chemotherapy.

[31]  Xilin Zhao,et al.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. , 2002, The New England journal of medicine.

[32]  J. Camm,et al.  Cardiotoxicity of fluoroquinolones. , 2002, The Journal of antimicrobial chemotherapy.

[33]  M. Kays,et al.  Levofloxacin Treatment Failure in a Patient with Fluoroquinolone‐Resistant Streptococcus pneumoniae Pneumonia , 2002, Pharmacotherapy.

[34]  C. Oliphant,et al.  Quinolones: a comprehensive review. , 2002, American family physician.

[35]  W. Watkins,et al.  Efflux pumps: their role in antibacterial drug discovery. , 2001, Current medicinal chemistry.

[36]  B. Dougherty,et al.  Efflux in bacteria: what do we really know about it? , 2001, Expert opinion on investigational drugs.

[37]  C. Tzeng,et al.  Synthesis and antibacterial evaluation of certain quinolone derivatives. , 2001, Journal of medicinal chemistry.

[38]  P. Empey,et al.  Levofloxacin Failure in a Patient with Pneumococcal Pneumonia , 2001, The Annals of pharmacotherapy.

[39]  W. Watkins,et al.  Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. , 2001, Journal of molecular microbiology and biotechnology.

[40]  D. Hooper.  Emerging mechanisms of fluoroquinolone resistance. , 2001, Emerging infectious diseases.

[41]  G. De Sarro,et al.  Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. , 2001, Current medicinal chemistry.

[42]  P. Ball.  Quinolone generations: natural history or natural selection? , 2000, The Journal of antimicrobial chemotherapy.

[43]  D. King,et al.  New classification and update on the quinolone antibiotics. , 2000, American family physician.

[44]  I. Morrissey,et al.  Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. , 2000, The Journal of antimicrobial chemotherapy.

[45]  S. Levy,et al.  Ineffectiveness of Topoisomerase Mutations in Mediating Clinically Significant Fluoroquinolone Resistance inEscherichia coli in the Absence of the AcrAB Efflux Pump , 2000, Antimicrobial Agents and Chemotherapy.

[46]  T. Gootz,et al.  Chemistry and Mechanism of Action of the Quinolone Antibacterials , 2000 .

[47]  D. Hamer,et al.  Use of the Quinolones for Treatment and Prophylaxis of Bacterial Gastrointestinal Infections , 2000 .

[48]  V. Andriole.  The Quinolones: Prospects , 2000 .

[49]  C. Nightingale,et al.  Pharmcokinetics and Pharmacodynamics of the Fluoroquinolones , 2000 .

[50]  L. Nicolle.  Use of Quinolones in Urinary Tract Infection and Prostatitis , 2000 .

[51]  K. Rolston.  Use of the Quinolones in Immunocompromised Patients , 2000 .

[52]  M. Niederman,et al.  Treatment of Respiratory Infections with Quinolones , 2000 .

[53]  J. Weigelt,et al.  Use of Quinolones in Surgery and Obstetrics and Gynecology , 2000 .

[54]  A. Karchmer.  Use of the Quinolones in Skin and Skin Structure (Osteomyelitis) and Other Infections , 2000 .

[55]  David H. Martin,et al.  Use of the Quinolones in Sexually Transmitted Diseases , 2000 .

[56]  L. Dembry,et al.  FLUOROQUINOLONE ANTIBIOTICS : ADVERSE EFFECTS AND SAFETY PROFILES , 1999 .

[57]  F. Alcaide,et al.  Fluoroquinolone Resistance Mutations in the parC,parE, and gyrA Genes of Clinical Isolates of Viridans Group Streptococci , 1998, Antimicrobial Agents and Chemotherapy.

[58]  S. Hill,et al.  Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract , 1998, Antimicrobial Agents and Chemotherapy.

[59]  L. Fisher,et al.  DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae , 1998, Antimicrobial Agents and Chemotherapy.

[60]  N. Kusano,et al.  Sparfloxacin Resistance in Clinical Isolates ofStreptococcus pneumoniae: Involvement of Multiple Mutations in gyrA and parC Genes , 1998, Antimicrobial Agents and Chemotherapy.

[61]  J. Domagala,et al.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Y. Kim,et al.  Novel fluoroquinolone antibacterial agents containing oxime-substituted (aminomethyl)pyrrolidines: synthesis and antibacterial activity of 7-(4-(aminomethyl)-3-(methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6- fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (LB20304). , 1997, Journal of medicinal chemistry.

[63]  S. Jones,et al.  Drug points: Quinolones may induce hepatitis , 1997, BMJ.

[64]  T. Gootz,et al.  Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects , 1996, Medicinal research reviews.

[65]  V. Andriole.  SESSION IV: PRESENT AND FUTURE ROLES OF QUINOLONES FUTURE ROLE AND USES OF THE QUINOLONES , 1994 .

[66]  J. Domagala.  Structure-activity and structure-side-effect relationships for the quinolone antibacterials. , 1994, The Journal of antimicrobial chemotherapy.

[67]  M. Nishida,et al.  In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116 , 1992, Antimicrobial Agents and Chemotherapy.

[68]  M. Gellert,et al.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[69]  J. Smith,et al.  Nalidixic acid and bacterial chromosome replication , 1976, Nature.